Highlights

• FY26 Revenue grew 8.8% to $648.4m; adjusted operating EBITDA rose 7.6% to $61.8m

• Statutory net loss narrowed dramatically to $67.2m from $150.0m in FY25, showing genuine improvement

• Dairy & Nutritionals adjusted EBITDA almost doubled to $21.6m — the standout segment in FY26

• Convertible note refinancing remains the critical Balance Sheet risk that overshadows operational progress

Noumi Limited (ASX:NOU) — formerly Freedom Foods — is an Australian food and beverage company that produces and markets a range of plant-based milk products (led by the Milklab brand), dairy and nutritional products, and cereal and snack foods. The company underwent a dramatic corporate restructuring after a financial crisis in 2020 that involved significant accounting restatements, management changes and asset restructuring. Since that nadir, Noumi has been on a multi-year operational recovery journey, attempting to rebuild its balance sheet, simplify its portfolio and grow the value of its genuinely differentiated brands — particularly Milklab, which has achieved strong penetration in the Australian and Asian café markets.

Latest Developments

Noumi's FY26 numbers show genuine operational improvement, although its balance-sheet situation remains the key issue. Revenue increased 8.8% to $648.4m, adjusted operating EBITDA rose 7.6% to $61.8m, and the statutory net loss narrowed dramatically to $67.2m, from $150.0m in FY25. Dairy & Nutritionals was the standout, with adjusted EBITDA almost doubling to $21.6m, while Plant-based Milks EBITDA fell to $43.1m as Noumi continued investing behind Milklab. The company is still facing a major financing issue around its convertible notes, so the improving operating performance needs to be considered alongside refinancing risk.

Industry Context

Australia's plant-based milk category has grown from a niche into a mainstream grocery and foodservice staple, with oat milk, almond milk and plant blends now commanding significant shelf space and café penetration. Milklab's professional barista positioning in the café channel has been a point of differentiation — coffee professionals have been a key influencer segment. However, the category has become increasingly competitive as dairy majors and international brands have launched their own plant-based variants, putting pressure on pricing and distribution. The dairy segment benefits from the ongoing structural Demand for nutritional products, particularly in China and Southeast Asia where Australian dairy provenance is valued.

Key Risks

• Convertible note refinancing risk — failure to refinance on acceptable terms could create a Liquidity event

• The $67.2m statutory net loss, while improved, still represents significant ongoing losses that erode equity

• Plant-based Milks EBITDA fell to $43.1m despite Investment in Milklab, raising questions about category profitability

• Competitive intensity in the plant-based milk category from dairy majors and international brands

• The company's complex financial history may reduce access to Capital Markets and increase funding costs

Key Catalysts to Watch

• Successful refinancing or repayment of the convertible notes, removing the most significant balance-sheet overhang

• Milklab international expansion — particularly in Asia — delivering revenue and Margin growth from a lower-competition market

• Dairy & Nutritionals EBITDA continuing to grow, providing a more stable Earnings base to underpin the balance sheet

• Reduction of the statutory net loss toward breakeven, demonstrating that the operational recovery is real and accelerating

• Any strategic review, asset sale or Equity Partnership that addresses the balance-sheet structure without excessive dilution

Conclusion

Noumi (ASX:NOU) is demonstrating genuine operational progress — 8.8% revenue growth and a dramatically narrowed statutory loss are meaningful milestones for a company that was in crisis just a few years ago. However, the convertible note financing issue remains the dominant near-term risk that could override positive operational developments. For investors, Noumi represents a high-risk, high-reward scenario: if the balance sheet is successfully restructured and Milklab continues to grow internationally, the equity upside could be significant. But the financing risk is real and must be navigated carefully.